289 related articles for article (PubMed ID: 30773984)
1. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
Flotho C
Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
[TBL] [Abstract][Full Text] [Related]
2. Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.
Leoncini PP; Vitullo P; Di Florio F; Tocco V; Cefalo MG; Pitisci A; Girardi K; Niemeyer C; Locatelli F; Bertaina A
Br J Haematol; 2018 Sep; 182(6):909-912. PubMed ID: 28771681
[No Abstract] [Full Text] [Related]
3. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
4. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
Fluhr S; Boerries M; Busch H; Symeonidi A; Witte T; Lipka DB; Mücke O; Nöllke P; Krombholz CF; Niemeyer CM; Plass C; Flotho C
Clin Epigenetics; 2016; 8():50. PubMed ID: 27158276
[TBL] [Abstract][Full Text] [Related]
5. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
6. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
8. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
[No Abstract] [Full Text] [Related]
9. Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.
Wilhelm T; Lipka DB; Witte T; Wierzbinska JA; Fluhr S; Helf M; Mücke O; Claus R; Konermann C; Nöllke P; Niemeyer CM; Flotho C; Plass C
Epigenetics; 2016; 11(2):110-9. PubMed ID: 26891149
[TBL] [Abstract][Full Text] [Related]
10. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
11. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
12. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
13. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
[TBL] [Abstract][Full Text] [Related]
14. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
15. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
16. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
[TBL] [Abstract][Full Text] [Related]
18. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
[TBL] [Abstract][Full Text] [Related]
19. RAS pathway mutations in juvenile myelomonocytic leukemia.
Emanuel PD
Acta Haematol; 2008; 119(4):207-11. PubMed ID: 18566538
[TBL] [Abstract][Full Text] [Related]
20. International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.
Schönung M; Meyer J; Nöllke P; Olshen AB; Hartmann M; Murakami N; Wakamatsu M; Okuno Y; Plass C; Loh ML; Niemeyer CM; Muramatsu H; Flotho C; Stieglitz E; Lipka DB
Clin Cancer Res; 2021 Jan; 27(1):158-168. PubMed ID: 33139265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
